Our clinical development plan, based on drug combinations that can potentially boost each response of the mechanism of action, has two main objectives. The primary objective is to obtain regulatory approval for REOLYSIN® as quickly as possible and is based on the compelling metastatic breast cancer survival data. The second objective is to expand REOLYSIN into commercially valuable new treatment areas that include immunotherapy and immunomodulatory (IMiD) agents in collaboration with pharmaceutical partners.

Program 1 - Chemo combinations (direct cell lysis)

This pathway is the basis of our metastatic breast cancer registration pathway and takes advantage of stressed tumor cells to initiate cell lysis.

Program 2 - Combination with (immunomodulators) IMiDs / targeted therapy (innate immune response)

This pathway currently explores the combination of Celgene's Imnovid® and Revlimid® in a groundbreaking immunotherapy trial. Our aim with this drug combination is to modulate the immune system to target myeloma.

Program 3 - Immunotherapy combinations (adaptive immune response)

This pathway approaches with checkpoint inhibitors embodied in the ongoing REOLYSIN + pembrolizumab study and possible future drug collaborations.